John Lim

equally divided between biotech and working at contract research organizations (CROs). He was most recently the Senior Vice President of clinical operations and regulatory affairs at Turning Point Therapeutics, Inc., where he helped develop their first and lead compound, repotrectinib. Prior to Turning Point, John was Vice President at Senhwa Biosciences Inc., and Senior Vice President at Cylene Pharmaceuticals, overseeing Clinical Operations and Regulatory Affairs at both companies. While working at CROs, John was Vice President for Research Operations at US Oncology Research, where he managed a network of cancer research sites. Prior to US Oncology, John held senior executive positions in clinical operations at Covance, Affiliated Research Centers, and Theradex. Before joining the industry, John was on the teaching faculty at the University of Otago Medical School in New Zealand. John graduated from the University of Otago in New Zealand with a Bachelor of Pharmacy degree, and he completed his Doctoral degree at the University of Kentucky.